Allergan has announced the successful completion of its acquisition of ZELTIQ® Aesthetics, a medical technology company behind a proprietary controlled-cooling fat reducing treatment.

The Dublin-based biopharmaceutical firm acquired ZELTIQ for a cash sum of approximately $2.4 billion.

With the acquisition, Allergan also acquires ZELTIQ’s flagship CoolSculpting® System, the sales leader in the fast-growing cash-pay body contouring segment of medical aesthetics. This makes body contouring the third addition to Allergan’s global aesthetics portfolio, joining its facial aesthetics and plastic surgery and regenerative medicine businesses.